Elephas Biosciences and Mithrl Pair Real-Time Tumor Profiling with Agentic AI to Unlock New Immunotherapy Response Insights

MADISON, Wis., April 15, 2026 – Elephas Biosciences Corporation (Elephas), a private company that has developed the elive™ ex vivo tumor profiling platform, announced a scientific collaboration with Mithrl, an AI company focused on accelerating research through its Scientific Decision Engine (SDE). Combining these innovative approaches establishes a foundation for integrating functional tumor profiling with AI-driven analysis to support more scalable and systematic discovery of novel immunotherapy response signals.